Genetic Diseases Haematological Disorders Anaesthesia
Conditions
Interventions
curarization monitoring
Sponsors
ARES ULB
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Sickle cell patients requiring elective laparoscopic surgery (defined as patients who did not require emergency surgery within 12 hours following admission to the hospital), as well as non-sickle cell patients matched to the same types of surgical procedures for the control group were included. After informed consent from patients, we included twenty two “22” patients in the sickle cell patients and twenty three "23" patients in the control group. There were three “03” main indications for surgery: cholecystectomy, appendectomy, and splenectomy.
Exclusion criteria
Exclusion criteria: We did not include patients age less than 18 and over 55 years, pregnancy, emergency surgery or surgery within the 12 hours following admission to the ward, predicted difficult ventilation or intubation, body mass index (BMI) over 30, known muscular disease, liver disease and in control group chronic renal disease and ASA 3 patients.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The onset time of action of rocuronium was longer in sickle cell patients [mean ± SD (extremes)], [378.22 ± 125.79 (110-600)] than in the control group [150.43 ± 35.62 (83-210)] (P < 0.01). Intubation conditions two “2” minutes after induction doses of rocuronium, as observed from TOF scan data, were not optimal: 20/2 in sickle cell patients and 15/8 in the control group (P = 0,05). The clinical duration of action was shorter in sickle cell patients [19.18 ± 7.12 (13-41)] when compared to the control group [28.96 ± 6.96 min (21-48) min] (P < 0.01). The time before the second dose of rocuronium was given, was shorter in the sickle cell patients group [27.68 ± 7.98 (19-49)] compared to the control group [9.91 ± 8.71 min (30-56 min)] (P < 0.01). The time after which the first response was observed following the second dose of rocuronium was not different in both groups. However, the time to the second response was shorter in the sickle cell patients group [32.64 ± 9.38 (17-53)] compared to the control group [41.48 ± 9.00 min (30-56 min)] (P = 0.002). | — |
Secondary
| Measure | Time frame |
|---|---|
| The onset time of action of rocuronium was longer in sickle cell patients [mean ± SD (extremes)], [378.22 ± 125.79 (110-600)] than in the control group [150.43 ± 35.62 (83-210)] (P < 0.01). Intubation conditions two “2” minutes after induction doses of rocuronium, as observed from TOF scan data, were not optimal: 20/2 in sickle cell patients and 15/8 in the control group (P = 0,05). The clinical duration of action was shorter in sickle cell patients [19.18 ± 7.12 (13-41)] when compared to the control group [28.96 ± 6.96 min (21-48) min] (P < 0.01). The time before the second dose of rocuronium was given, was shorter in the sickle cell patients group [27.68 ± 7.98 (19-49)] compared to the control group [9.91 ± 8.71 min (30-56 min)] (P < 0.01). The time after which the first response was observed following the second dose of rocuronium was not different in both groups. However, the time to the second response was shorter in the sickle cell patients group [32.64 ± 9.38 (17-53)] compared to the control group [41.48 ± 9.00 min (30-56 min)] (P = 0.002). | — |
Countries
Cameroon
Contacts
Public ContactJacob SOUOPGUI
Expert for University Cooperation and Development
Outcome results
None listed